If I heard Dr. Jay correctly... In addition to
Post# of 148096
In addition to CRP, "EN-RAGE" is the other primary endpoint that will be measured in the upcoming inflammatory trial. More info here:
https://pubmed.ncbi.nlm.nih.gov/25341801/
Also (from a different website):
EN-RAGE is a ligand for the receptor for advanced glycation end products. The protein encoded by this gene is a member of the S100 family of proteins. S100 proteins are localized in the cytoplasm and/or nucleus of a wide range of cells and are involved in the regulation of a number of cellular processes such as cell cycle progression and differentiation. EN-RAGE is proposed to be involved in specific calcium-dependent signal transduction pathways, and its regulatory effect on cytoskeletal components may modulate various neutrophil activities. Interaction of EN-RAGE with cellular RAGE on endothelium, mononuclear phagocytes, and lymphocytes triggers cellular activation with generation of key proinflammatory mediators. In murine models, blockade of ENRAGE/RAGE quenched delayed-type hypersensitivity and inflammatory colitis by arresting activation of central signaling pathways and expression of inflammatory gene mediators.
On another note, this may be of interest too:
https://thisvsthat.io/joint-venture-vs-licensing
I remain... #BULLISH!
P.S. Regarding CYDY's prospects: https://www.youtube.com/watch?v=OEH4jaQpOt4